Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

“Psoriasis shares common underlying biological pathways with several ... This trial is focused on the treatment of non-segmental vitiligo. "Vyne doses first participant in Phase Ib plaque ...

Plaque psoriasis affects millions worldwide and is characterized by inflamed, scaly plaques on the skin. VYNE's BET inhibitors aim to offer a non-biologic treatment option that could manage the ...

Psoriasis is a chronic skin condition ... Some people with severe disease might combine a non-biologic systemic treatment ...

The Phase 1b trial of VYN202 will evaluate its safety, pharmacokinetics, and efficacy in moderate-to-severe plaque psoriasis ... aims to offer a novel, non-biologic treatment for chronic immune ...

Phase 1b trial designed to provide key insights into VYN202’s potential across a range of chronic, immune-mediated diseases BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc.

SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...